Name	Folde r	Ch art er	Min ute s	Calen dar feed	Ма	il-list	Cor	itacts
Tissues, Technolo gy, and Data Collection	wg-ttd-c ection-fo er	-	ol d-co ti lectio -c n-mi	l collec o cs	/g-ttd-	wg-ttd-collection@l hubmapconsortium		Clive Wasserfall - Co-chair   clive@ufl.edu Long Cai - Co-chair   Icai@caltech.e du Jocelyn Kishi - Knowledge Manager   jkishi@g.harvar d.edu

Please use this time to best suit the needs of your Working Group. We recommend introducing team members that have not met, reviewing past achievements of the group, upcoming plans, and ensuring an action plan is in place with members assigned. At a minimum please review your charter and capture below the following information for NIH. Please take notes in this document as a record of the discussion.

Suggested agenda:

- Roll call; introduce new members
  - Clive, Anup, Richard, Bill, Kristen, Ellen, Genie, Kevin, Pehr, Trevor, Nico, Aaron, Elizabeth, Marc
- Progress during the past year (please summarize key achievements; a few sentences will suffice)
  - Protocols.io URL can change, need to cite DOI
  - UUID HIVE generate IDs IDs are needed to submit data to HIVE in order to track provenance
  - Need a SOP for what needs to be done as part of tissue collection
  - Can we incorporate cell phone photos into Katy's CCF app?
  - Get Katy to come and present her app at Nov meeting?

- Giant metadata scheme developed by Ajay VU has 143 donors so far; is it possible for Pitt to transcribe that many clinical notes?
- STARFISH working with HCA to take what they've done
- Plans for the upcoming year
  - What are they key activities planned for the upcoming year? (a few bullet points will suffice)
    - Collaborative talks scheduled
    - Rigor & reproducibility
    - Reagents NIH(?) will compile a list of antibodies in use across the different groups and something about their quality
    - Benchmarking
    - Simple cross-site comparison share issue across multiple sites, and everyone carry out 3 simple assays - 1) RIN score, 2) autofluorescence, 3) IF / DAPI. Tissues get sent by end of calendar year; results back by end of March
    - Affinity reagents what should we be prioritizing? Compile a list of antibodies currently in use / what we want to use / high profile targets; e.g. SOX2 - GE has their version, not one commercially available
  - Are there action items from the WG that need to be presented to the SC?
  - Will additional resources be needed for any activities?
- Administrative issues
  - Internal communication are channels working? Working fine
  - Any changes to charter? No (<u>https://drive.google.com/open?id=1L6Rbd1Bf1P7dU5\_wHGGCM75xvn0bqGFU</u> <u>C0GbqD8pb1U</u>)
  - Meeting schedule changes? Current schedule is fine
  - Do you want to rotate co-chairs ./ knowledge manager?
- Any Other Business